We are live on ! Find out more
BBOT

BridgeBio Oncology
BBOT

29 hedge funds and large institutions have $167M invested in BridgeBio Oncology in 2024 Q1 according to their latest regulatory filings, with 29 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

84.98% more ownership

Funds ownership: 0% → 84.98% (+85%)

Holders
29
Holders Change
+29
Holders Change %
–
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
29
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
+$30.1M
2
BlackRock
BlackRock
New York
+$15.5M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$14.5M
4
Citadel Advisors
Citadel Advisors
Florida
+$13.8M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$11.7M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
1
Cormorant Asset Management
Massachusetts
$30.3M +$30.1M +2,909,000 New
BlackRock
2
BlackRock
New York
$15.6M +$15.5M +1,500,000 New
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$14.6M +$14.5M +1,400,000 New
Citadel Advisors
4
Citadel Advisors
Florida
$13.8M +$13.8M +1,332,453 New
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$11.7M +$11.7M +1,130,677 New
Millennium Management
6
Millennium Management
New York
$11.5M +$11.4M +1,105,790 New
SC
7
Sculptor Capital
New York
$7.33M +$7.3M +705,000 New
FCM
8
Farallon Capital Management
California
$6.21M +$6.21M +600,000 New
CC
9
Commodore Capital
New York
$5.2M +$5.18M +500,000 New
GPP
10
Great Point Partners
Connecticut
$5.2M +$5.18M +500,000 New
PA
11
Perceptive Advisors
New York
$5.2M +$5.18M +500,000 New
SCM
12
Silverarc Capital Management
Massachusetts
$5.2M +$5.18M +500,000 New
SFM
13
Soros Fund Management
New York
$4.94M +$4.92M +475,000 New
ACM
14
ADAR1 Capital Management
Texas
$4.2M +$4.18M +403,500 New
T. Rowe Price Investment Management
15
T. Rowe Price Investment Management
Maryland
$4.14M +$4.14M +400,000 New
GTC
16
Ghost Tree Capital
New York
$3.12M +$3.11M +300,000 New
LCM
17
Laurion Capital Management
New York
$3.1M +$3.11M +300,000 New
AAA
18
Affinity Asset Advisors
New York
$2.59M +$2.59M +250,000 New
OCA
19
Octagon Capital Advisors
New York
$2.59M +$2.59M +250,000 New
Wellington Management Group
20
Wellington Management Group
Massachusetts
$2.09M +$2.09M +202,160 New
SC
21
Stempoint Capital
New York
$2.08M +$2.07M +200,000 New
Two Sigma Investments
22
Two Sigma Investments
New York
$1.97M +$1.96M +189,285 New
WP
23
Woodline Partners
California
$1.11M +$1.1M +106,705 New
MCM
24
Moore Capital Management
New York
$1.03M +$1.04M +100,000 New
Walleye Capital
25
Walleye Capital
New York
$955K +$955K +92,224 New
1
2

BBOT Hedge Fund Activity: Q1 2024 in Review

29 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Oncology (BBOT) for Q1 2024, worth a combined $167M.

Buyers outnumbered sellers: 29 funds opened new BBOT positions and 0 closed out — a net gain of 29 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $30.1M.

  • 29 institutional investors held BridgeBio Oncology (BBOT) as of Q1 2024, up from 0 in Q4 2023.
  • Funds reported $167M of BridgeBio Oncology stock for Q1 2024.
  • 29 funds opened new BridgeBio Oncology positions in Q1 2024 and 0 closed out, a net change of +29 holders.
  • The largest BridgeBio Oncology buyer in Q1 2024 was Cormorant Asset Management, an estimated $30.1M added.

Based on aggregated 13F filings for Q1 2024.